En

Miosta H®

It is a new receptor drug for the treatment of nutritional dystrophy and protein-energy deficiency (PEM) in cattle, sheep and goats.

Download the full instructions Results of Miosta H®

Violation of the absorption and assimilation of the protein component of feed by the animal body, chronic digestive disorders of animals leading to alimentary dystrophy of livestock.

The active components of the drug are a complex molecule consisting of a peptide - LEAP-2 (a specific antigen) connected to a protein binding various polysaccharides.

Increase in body weight
Increase in milk yields and fat content
Improves the immunity and general condition of the animal
Helps in the regeneration of hooves, bones and tendons
Stimulates the work of the reproductive system of the body

The use of Miosta H® contributes to

Miosta H® is rapidly absorbed from the injection site, reaching a peak concentration in blood plasma 30 minutes after administration, and is slowly excreted from the body. It accumulates in neutrophils and alveolar macrophages, as a result of which its increased concentration in lung tissues is achieved. It is excreted from the body mainly by the kidneys unchanged; the half-life is about 90 hours.

Advantages of using Miosta H®

Additional profit of meat production up to 15%
Reduction of fixed production costs
Shortening the livestock breeding cycle
Safe ready-made food

Research results

The study was conducted on 3 groups, 30 goals in each group

Increase in the total weight gain of calves, kg

  • Control group
  • Who received Miosta H® injections
  • Who received injections of Dufalite

Research results

The study was conducted on 3 groups, 30 goals in each group

Increase in the average daily weight gain of calves, kg

  • Control group
  • Who received Miosta H® injections
  • Who received injections of Dufalite

Research results

The study was conducted on 2 groups, 30 goals in each group

Increase in daily milk yield, l

  • Who received Miosta H® injections
  • Control group
Ask a question